EMEA-002149-PIP01-17
Key facts
| Active substance |
DaxibotulinumtoxinA
|
| Therapeutic area |
Other
|
| Decision number |
P/0220/2017
|
| PIP number |
EMEA-002149-PIP01-17
|
| Pharmaceutical form(s) |
Powder for solution for injection
|
| Condition(s) / indication(s) |
Treatment of glabellar lines
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Revance Therapeutics Inc
|
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|